

PATENT Attorney Docket No. MRK-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Cardy et al.

CONFIRMATION NO.: 5220

SERIAL NO.:

08/737,457

GROUP NO.:

1644

FILING DATE:

May 15, 1995

EXAMINER:

Ewoldt, G.R.

TITLE:

Improvements in or Relating to Peptide Delivery

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

Sir:		•
1.	\boxtimes	This replies to the Office communication dated <u>January 13, 2003</u> .
		A copy of the Office communication is enclosed.
2.	Subr	nitted herewith is/are (check each item as applicable)
	A.	a paper copy of the Sequence Listing for this application with each sequence assigned a separate identifier; and
	В.	a CD of the Sequence Listing for this application with each sequence assigned a separate identifier; and
	C.	a copy, in computer readable form, of the Sequence Listing for this

Applicants respectfully request entry of the Sequence Listing, which is provided in both paper and computer-readable form in the above-identified application. The Sequence Listing submitted herewith is intended to replace the Sequence Listing currently on file in this application.

Submission Of Paper Copy And/Or Computer Readable Copy Of Sequence Listing For Invention Containing Nucleotide And/Or Amino Acid Sequence For invention Containing Nucleonial No. 08/737,457
Attorney Docket No. MRK-003
age 2 of 2

STATEMENT

3.	I here	eby sta	te that:			
		(complete applicable items A, B and/or C)				
	A.	\times herew	the contents of the paper and computer readable copy submitted with are the same; and			
	В.	are th	the content of the CD and computer readable copy submitted herewith ne same; and			
	C.	the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on pages to of the original specification as filed; and				
	D.	\boxtimes	this submission includes no new matter.			
Respectfully submitted,						
Reg Tel		48,645 (617) 2	- 1			

07/12/04

Express Mail Mailing Label No. EV289510612ÛS

29

+						122 452	
	(1)	1.6		Serial Number		/737,457	
Me g and			Filing Date			May 15, 1995	
			First Named Inventor		Ca	rdy 2011 111 111	
	TRANSMITTA	2004 [] L	Group Art U	Jnit	164	44 BECEWED "	
	TRANSMITTA FORM	CAROS	Examiner N	Examiner Name		Ewoldt, G.R.	
	FORM	معمناه بم	Attorney Do	ocket No.	MI	RK-003 JUL 1 6 2004	
			Patent No.		No	ot applicable	
			Issue Date		No	ot applicable	
	<u></u>	ENC	CLOSURES (c	heck all that apply)			
⊠ F	Fee Transmittal Form			e to File Missing		Notice of Appeal to Board	
. —		_	Parts of Applic			of Patent Appeals and Interferences	
	☐ Check Attached☐ Copy of FeeTransmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)	
	Amendment/Response		Request For C Examination (Status Inquiry	
	☐ Preliminary ☐ After Final		Transmittal		Ø	Return Receipt Postcard	
	Affidavits/declaration(s) Letter to Official Draftsperson		Power of Attor (Revocation of	rney f Prior Powers)		Certificate of First Class Mailing under 37 C.F.R. 1.8	
	including Drawings [Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8	
	Petition for Extension of Time		Executed Declaration and Power of Attorney for Utility or Design Patent Application		⊠	Additional Enclosure(s) (please identify below)	
			· wont i ippnou			Notification Regarding Change in	
	Information Disclosure Statement (2 pages)		Small Entity S	tatement		Status	
	Form PTO-1449 Copies of IDS Citations (CD(s) for large	e table or computer			
	Certified Copy of Priority Document(s)	_	Amendment After Allowance		07/	/15/2004 KKEMP1 00000003 08737457	
	Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Request for Co Correction Certificate duplicate)	of Correction (in		FC:1461 1955. 0 0	
COR	RESPONDENCE ADDRESS			SIGNATURE BL	OCK		
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thil High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-70 Fax No.: (617) 248-71			ibeault, LLP	Date: July 9, 2004 Reg. No. 48,645 Tel. No.: (617) 248- Fax No.: (617) 248-		Respectfully submitted, Brian A. Fairchild, Ph.D. Attorney for the Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110	

Express Mail Mailing Label Nov. EV289510612US

				Complete if Known		
FOR A NICH STORE A I	tion Serial Number 08/737,457					
FEETRANSMITTAL	Filing Date			May 15, 1995		
/ FX 2004	First Ma	Condu				
	rust na	amed Inventor Cardy 2014 JUL 14 AN III: 3			: 30	
JAN. 3 9 2004 🙀	Group A	Art Unit		1644		
	Examine	er Name		Ewoldt, G.R.		
	Attorney	y Docket No.		MRK-003		
METHOD OF PAYMENT			FE	E CALCULATION (continued)		
1. A Payment Enclosed:		3. ADDITI				
☐ Check ☐ Money Order ☐ Other		Large	Small			
		Entity	Entity	JUL 1 6 2004		
2. A The Commissioner is hereby authorized to cre	dit	Fee	Fee	Fee Description	Fee Paid	
or charge any fee indicated below for this subr	nission	(\$)	(\$)	OFFICE OF PENNON'S		
to Deposit Account No. 20-0531.				_		
Required Fees (copy of this sheet enclose		130	65	Surcharge - late filing fee or oath		
Additional fee required under 37 CFR 1	.16 and	50	25	Surcharge - late provisional filing fee		
1.17.				or cover sheet		
Overpayment Credit.		130	130	Non-English specification		
3. Applicant claims small entity status.		2,520	2,520	Request for ex parte reexamination		
FEE CALCULATION		110	55	Extension for reply within first month		
1. FILING FEE		420	210	Extension for reply within second		
Y Post (050	425	month		
Large Entity	F W	950	475	Extension for reply within third month		
Fee (\$) Fee Description	Fee Paid	1480	740	Extension for reply within fourth month		
		2010	1005	Extension for reply within fifth month		
770 Utility filing fee		330	165	Notice of Appeal		
340 Design filing fee		330	165	Filing a brief in support of an appeal		
160 Provisional filing fee		290	145	Request for oral hearing		
		130	130	Petitions to the Commissioner		
		180	180	Submission of Information Disclosure		
	Amount			Statement		
Filed Extra		770	385	Filing a submission after final		
				rejection (37 CFR 1.129(a))		
Total Claims = $x $ 18.00 =$		770	385	For each additional invention to be		
1d		100	100	examined (37 CFR 1.129(b))		
Independent Claims = $x \$ 86.00 =$		100	100	Certificate of Correction for applicant's error		
Multiple Dependent Claim(s), if any \$290.00 =		Other fee (Spe	cify)	• •	1955.00	
			,	in Notification Regarding Change in	1,555.00	
				Status		
TOTAL:						
SMALL ENTITY DISCOUNT:	0.00	1				
SUBTOTAL (1) (\$) 2. AMENDMENT CLAIM FEES	0.00	1				
Claims Highest No. Present Rate	Fee Paid	l		SUBTOTAL (3) (\$)	1955.00	
Remaining Previously Extra				(3)	.,,,,,,,,	
Total - = $x \$ 18.00 =$				SUBTOTAL (1)	0.00	
Indep = x \$ 86.00 =				` ′ 1=	0.00	
First Presentation of Multiple Dep. + \$290.00 =					1955.00	
Claim		1		`` <u></u>		
TOTAL:						
SMALL ENTITY DISCOUNT:	N 0 0 C	1		mom. t	1055.00	
SUBTOTAL (2)	00.00	4		TOTAL(\$)	1955.00	
CORRESPONDENCE ADDRESS	SIGNATURE BLOCK					
Direct all correspondence to:				Respectfully submitted		
Patent Administrator			•••	12. 1. [1]		
Testa, Hurwitz & Thibeault, LL	Date: July 9, 2	2004	me now			
High Street Tower-125 High St	Reg. No.: 48,645 Brian A. Fairchild, Ph.D.					
Boston, MA 02110	Tel. No.: (617		,			
Tel. No.: (617) 248-7000	Fax No.: (617) 248-7100 Testa, Hurwitz & Thibeault, LLP					
Fax No.: (617) 248-7100]		High Street Tower-125 High S	Street	
		I		Boston MA 02110		





PATENT Atty. Docket No. MRK-003

2004 JUL 14 AM 11: 30

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Cardy et al.

CONF. NO.

5220

SERIAL NO.:

08/737,457

GROUP NO.:

1644

JUL 1 6 2004

FILING DATE:

May 15, 1995

EXAMINER:

Ewoldt, G.R.OFFICE OF PETITIONS

TITLE:

IMPROVEMENTS IN OR RELATING TO PEPTIDE

DELIVERY

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

NOTIFICATION REGARDING CHANGE IN STATUS

Sir:

Pursuant to 37 C.F.R. § 1.27(g)(2), Applicants notify the U.S. Patent and Trademark Office (USPTO) that status as a small entity is no longer appropriate for the above-identified patent application.

Through error, the USPTO was not notified of a loss of entitlement to small entity status in May of 2001. Applicants request that this error be excused under 37 C.F.R. § 1.28(c). Applicants submit herewith a check in the amount of \$1955.00 for payment of the total deficiency payment owed as itemized below in accordance with 37 C.F.R. § 1.28(c)(2). Applicants believe that no other fees are due with this submission. Nevertheless, please charge any other required fees to Deposit Account No. 20-0531.

Type of Fee	Fee Paid & Date Paid	Current Fee Amount	Deficiency
	(Small Entity Amount)	(Non-Small Entity)	(Amount Owed)
Basic Filing Fee	\$345.00 on May 25, 2001	\$770.00	\$425.00
Excess Total Claims	\$18.00 on May 25, 2001	\$36.00	\$18.00
Fee (2 extra)			
Excess Independent	\$80.00 on May 25, 2001	\$172.00	\$92.00
Claims Fee (2 extra)			

Notification Regarding Change in Status U.S.S.N. 08/737,457 Page 2 of 2

JUL 2 9 2004

Type of Fee	Fee Paid & Date Paid	Current Fee Amount	Deficiency
	(Small Entity Amount)	(Non-Small Entity)	(Amount Owed)
Multiple Independent Claim Fee	\$135.00 on May 25, 2001	\$290.00	\$155.00
One-month Extension of Time Fee	\$55.00 on May 25, 2001	\$110.00	\$55.00
One-month Extension of Time Fee	\$55.00 on August 13, 2001	\$110.00	\$55.00
Three-month Extension of Time Fee	\$460.00 on April 15, 2002	\$950.00	\$490.00
Petition for Revival of an Unintentionally Abandoned Application	\$665.00 on February 26, 2004	\$1,330.00	\$665.00
Total Deficiency			\$1955.00

Respectfully submitted,

Date: July 9, 2004 Reg. No.: 48,645

Tel. No. (617) 248-7697 Fax: (617) 248-7100

3090727

Brian A. Fairchild, Ph.D. Attorney for Applicants Testa, Hurwitz, & Thibeault

High Street Tower 125 High Street

Boston, Massachusetts 02110





UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMESSI NEROS PATENTS AND TRADEMARKS
Washington 1 (2) 2020

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
08/737.457	03/12/1997	DONALD LEONARD NICHOLAS CARDY	960670. PRIC	5220
75	90 01/13/2003	•		
ORRIN M HA			ÊXAMI	NER
	TIONAL CENTRE		EWOLDT. C	GERALD R
	AVENUE SOUTH S, MN 554023325		ART UNIT	PAPER NUMBER
		=OPI	1644 DATE MAILED: 01/13/2003	37

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

EXAMINER				
ART UNIT	PAPER NUMBER			
	37			

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. Specifically, the sequence in Figure 10 and in the seventh paragraph at page 8 of the specification must be brought into sequence compliance.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Christina Chan whose telephone number is (703) 308-3973. The fax number for the organization where this application is assigned is (703) 308-4242.

G.R. Ewoldt, Ph.D. Patent Examiner Tech Center 1600

December 27, 2002

Ap can No.: 08/737,457

NOTICE TO COMPLY WITH TO QUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND MINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

N	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Аp	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entrinto the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 SentIn Software Program Support Technical Assistance
	To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



UNITED STAY, TENT AND TRADEMARK OFFICE





COMMISSIONER FOR PATE UNITED STATES PATENT AND TRADEMARK OFFICE P.O. Box 1450 ALEXANDRIA, VA 22313-1450

www.uspto.go

Paper No. 44

Orrin M. Haugen Haugen and Nikolai 820 International Centre 900 Second Avenue South Minneapolis, MN 55402-3325 **REC'D** APR 1 2 2004

COPY MAILED

APR 0 9 2004

OFFICE OF PETITIONS

In re Application of Cardy et al. Application No. 08/737,457 Filed: March 12, 1997 Attorney Docket No. 960670.CNC

ON PETITION

This is a decision on the petition under 37 CFR 1.137(b), filed March 1, 2004, to revive the above-identified application.

The petition is **DISMISSED**.

Any request for reconsideration of this decision must be submitted within TWO (2) MONTHS from the mail date of this decision. Extensions of time under 37 CFR 1.136(a) are permitted. The reconsideration request should include a cover letter entitled "Renewed Petition under 37.CFR 1.137(b)." This is not final agency action within the meaning of 5 U.S.C. § 704.

The above-identified application became abandoned for failure to reply in a timely manner in reply to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and /or Amino Acid Sequence Disclosures mailed January 13, 2003. The Notice set a period for reply of (30) Thirty Days from the mail date of the Notice. No extensions of time under the provisions of 37 CFR 1.136 have been obtained. Accordingly, the application became abandoned on February 14, 2003.

A grantable petition under 37 CFR 1.137(b) must be accompanied by: (1) the required reply, unless previously filed; (2) the petition fee as set forth in 37 CFR 1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional; and (4) any terminal disclaimer (and fee as set forth in 37 CFR 1.20(d)) required by 37 CFR 1.137(c). Where there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137 was unintentional, the Commissioner may require additional information. See MPEP 711.03(c)(III)(C) and (D). The instant petition lack(s) item(s) (1).

Item (1), The reply filed March 1, 2004 fails to comply with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed January 13, 2003. Accordingly, this application cannot be revived until a complete reply has been submitted.

Further correspondence with respect to this matter should be addressed as follows:

By mail:

Mail Stop Petitions

Box DAC

Washington, D.C. 20231

By facsimile:

(703) 872-9306

Attn: Office of Petitions

By hand:

2201 South Clark Place

Crystal Plaza 2, Lobby

Room 1B03

Arlington, VA 22202

Telephone inquiries concerning this decision should be directed to Latrice Bond at (703) 308-6911.

Latrice Bond

Paralegal Specialist

Sature Bon

Office of Petitions

Office of the Deputy Commissioner

for Patent Examination Policy